CLINICAL TRIALS PROFILE FOR CRIZOTINIB

All Clinical Trials for CRIZOTINIB

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00828919 ↗	Continuing Access to Axitinib (A406- AG- 013736 ) For Patients Previously Receiving AG 013736 In Clinical Trials	Active, not recruiting	Pfizer	N/A	2003-03-07	To allow continuation of axitinib (AG 013736) treatment to patients experiencing clinical benefit in a closing axitinib trial
NCT00939770 ↗	Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma	Completed	National Cancer Institute (NCI)	Phase 1/Phase 2	2009-09-21	This phase 1/2 trial the studies side effects and best dose of crizotinib and to see how well it works in treating young patients with solid tumors or anaplastic large cell lymphoma that has returned after a period of improvement or does not respond to treatment. Crizotinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. (Phase 1 completed 2/15/13)
NCT00939770 ↗	Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma	Completed	Pfizer	Phase 1/Phase 2	2009-09-21	This phase 1/2 trial the studies side effects and best dose of crizotinib and to see how well it works in treating young patients with solid tumors or anaplastic large cell lymphoma that has returned after a period of improvement or does not respond to treatment. Crizotinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. (Phase 1 completed 2/15/13)
NCT00939770 ↗	Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma	Completed	Children's Oncology Group	Phase 1/Phase 2	2009-09-21	This phase 1/2 trial the studies side effects and best dose of crizotinib and to see how well it works in treating young patients with solid tumors or anaplastic large cell lymphoma that has returned after a period of improvement or does not respond to treatment. Crizotinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. (Phase 1 completed 2/15/13)
NCT01082380 ↗	Radiolabeled [14C]PF-02341066 Study To Investigate The Absorption, Metabolism And Excretion In Healthy Male Volunteers	Completed	Pfizer	Phase 1	2010-03-01	The rationale for this study is to investigate the absorption, metabolism and excretion of [14C]PF 02341066 and characterize plasma, fecal and urinary radioactivity, and identify any metabolites, if possible, of [14C]PF 02341066 in humans.

Clinical Trial Conditions for CRIZOTINIB

Condition Name

Condition Name for CRIZOTINIB
Intervention	Trials
Non-Small Cell Lung Cancer	30
Healthy	10
Carcinoma, Non-Small-Cell Lung	10
Lung Cancer	6

Condition MeSH

Condition MeSH for CRIZOTINIB
Intervention	Trials
Carcinoma, Non-Small-Cell Lung	73
Lung Neoplasms	63
Neoplasms	21
Lymphoma	16

Clinical Trial Locations for CRIZOTINIB

Trials by Country

Trials by Country for CRIZOTINIB
Location	Trials
United States	959
China	177
Italy	116
Japan	82
Spain	77

Trials by US State

Trials by US State for CRIZOTINIB
Location	Trials
California	42
Texas	40
New York	38
Massachusetts	37
Florida	35

Clinical Trial Progress for CRIZOTINIB

Clinical Trial Phase

Clinical Trial Phase for CRIZOTINIB
Clinical Trial Phase	Trials
Phase 4	4
Phase 3	20
Phase 2/Phase 3	3

Clinical Trial Status

Clinical Trial Status for CRIZOTINIB
Clinical Trial Phase	Trials
Recruiting	49
Completed	48
Active, not recruiting	24

Clinical Trial Sponsors for CRIZOTINIB

Sponsor Name

Sponsor Name for CRIZOTINIB
Sponsor	Trials
Pfizer	56
National Cancer Institute (NCI)	17
Hoffmann-La Roche	10

Sponsor Type

Sponsor Type for CRIZOTINIB
Sponsor	Trials
Other	164
Industry	148
NIH	17